新生儿分离和组合生长激素缺乏症的管理:当前状况
Stefano Stagi1,2, Maria Tufano3, Nicolò Chiti1
1Department of Health Sciences, University of Florence, 50139 Florence, Italy.
International journal of molecular sciences
|June 28, 2023
概括
先天性生长激素缺乏症 (GHD) 是一种罕见的垂体疾病. 通过实验室检测及早诊断和迅速的生长激素替代疗法可以改善患者的治疗结果.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 先天性生长激素缺乏症 (GHD) 源于 pituitary 腺发育问题.
- GHD可以单独发生或与其他垂体激素缺陷一起发生.
- 遗传因素可能是先天性GHD的一些病例的基础.
研究的目的:
- 总结一下先天性生长激素缺乏症的关键方面.
- 突出GHD的诊断标准和治疗方法.
- 强调早期干预在GHD管理中的好处.
主要方法:
- 对GHD的临床迹象和症状的审查.
- 强调实验室诊断分析而不是成像.
- 讨论激素替代疗法方案的讨论.
主要成果:
- 临床表现包括低血糖症,新生儿胆固醇症和小阴茎.
- 实验室检测是GHD的首选诊断方法.
- 早期生长激素替代疗法产生了显著的好处.
结论:
- 及时诊断和治疗先天性GHD至关重要.
- 早期生长激素治疗可以改善生长,新陈代谢和神经发育.
- 管理重点是实验室确认和及时的激素替代.
相关概念视频
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Nature and Nurture
20.6K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.6K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
205
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
205
Cystic Fibrosis: Management
199
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
199
Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
Insulin: Dosing Regimen and Adverse Effects
214
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
214


